🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Zhejiang Jingxin Pharmaceutical Co., Ltd. (SHE:002020)
China flag China · Delayed Price · Currency is CNY
10.89
-0.43 (-3.80%)
Nov 20, 2026, 3:04 PM CST

SHE:002020 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
3,9673,9804,0863,9203,7173,401
Other Revenue
89.8389.8372.7378.8962.8165.06
4,0574,0694,1593,9993,7803,467
Revenue Growth
1.47%-2.15%3.99%5.79%9.04%6.40%
Cost of Revenue
2,0342,0632,0981,9881,7741,547
Gross Profit
2,0232,0072,0612,0112,0061,920
Selling, General & Admin
804.63822.87916.32994.61984.94970.72
Research & Development
356.85367.99383.48400.79367.04334.14
Other Operating Expenses
43.9239.7833.5230.0936.1926.57
Operating Expenses
1,1951,2371,3461,4321,3921,342
Operating Income
828.03769.85714.56579.08613.8577.8
Interest Expense
-1.29-3.96-7.74-7.31-6.01-4.97
Interest & Investment Income
72.0378.5880.266.7185.0596.29
Currency Exchange Gain (Loss)
-10.02-10.022.933.4314.43-3.84
Other Non Operating Income (Expenses)
-45.04-2.04-3.4-0.97-3.21-7.19
EBT Excluding Unusual Items
843.71832.42786.54640.94704.06658.09
Impairment of Goodwill
-12.88-12.88----
Gain (Loss) on Sale of Investments
-5.939.47-42.3724.4410.157.23
Gain (Loss) on Sale of Assets
5.87-0.572.596.860.61-0.48
Asset Writedown
-44.8-2.81-0.07-0.01-0.07-8.42
Other Unusual Items
38.738.797.335.8135.5643.12
Pretax Income
824.66864.33843.98708.04750.32699.54
Income Tax Expense
106.7197.66124.8584.6282.4981.57
Earnings From Continuing Operations
717.95766.67719.13623.42667.82617.96
Minority Interest in Earnings
-8.47-8.69-7.16-4.52-5.57-5.42
Net Income
709.48757.98711.96618.9662.25612.54
Net Income to Common
709.48757.98711.96618.9662.25612.54
Net Income Growth
-0.43%6.46%15.04%-6.55%8.12%-6.21%
Shares Outstanding (Basic)
815824858860860817
Shares Outstanding (Diluted)
815824858860860817
Shares Change
-1.86%-3.95%-0.21%-0.06%5.31%2.55%
EPS (Basic)
0.870.920.830.720.770.75
EPS (Diluted)
0.870.920.830.720.770.75
EPS Growth
1.46%10.84%15.28%-6.49%2.67%-8.54%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
737.45578.5475.52273.32340.2-33.37
Free Cash Flow Per Share
0.900.700.550.320.40-0.04
Dividend Per Share
0.3500.3500.3500.3000.3000.300
Dividend Growth
0%0%16.67%0%0%2.84%
Gross Margin
49.86%49.31%49.56%50.30%53.06%55.39%
Operating Margin
20.41%18.92%17.18%14.48%16.24%16.67%
Profit Margin
17.49%18.63%17.12%15.48%17.52%17.67%
Free Cash Flow Margin
18.18%14.22%11.43%6.83%9.00%-0.96%
EBITDA
1,0841,037996.1784.87766.56713.89
EBITDA Margin
26.73%25.48%23.95%19.63%20.28%20.59%
D&A For EBITDA
256.32267.13281.55205.79152.76136.09
EBIT
828.03769.85714.56579.08613.8577.8
EBIT Margin
20.41%18.92%17.18%14.48%16.24%16.67%
Effective Tax Rate
12.94%11.30%14.79%11.95%10.99%11.66%
Revenue as Reported
4,0574,0694,1593,9993,7803,467
Advertising Expenses
-----5.13